Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Research & Development: 2018-2024

Historic Research & Development for Phathom Pharmaceuticals (PHAT) over the last 7 years, with Dec 2024 value amounting to $34.1 million.

  • Phathom Pharmaceuticals' Research & Development fell 19.16% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.9 million, marking a year-over-year decrease of 12.91%. This contributed to the annual value of $34.1 million for FY2024, which is 31.70% down from last year.
  • As of FY2024, Phathom Pharmaceuticals' Research & Development stood at $34.1 million, which was down 31.70% from $49.9 million recorded in FY2023.
  • Phathom Pharmaceuticals' 5-year Research & Development high stood at $98.1 million for FY2020, and its period low was $34.1 million during FY2024.
  • Its 3-year average for Research & Development is $51.8 million, with a median of $49.9 million in 2023.
  • In the last 5 years, Phathom Pharmaceuticals' Research & Development skyrocketed by 381.73% in 2020 and then plummeted by 31.70% in 2024.
  • Phathom Pharmaceuticals' Research & Development (Yearly) stood at $98.1 million in 2020, then fell by 26.30% to $72.3 million in 2021, then declined by 1.24% to $71.4 million in 2022, then plummeted by 30.15% to $49.9 million in 2023, then slumped by 31.70% to $34.1 million in 2024.